# q07 rev 0 raw returns (tested_sha256 83dc1c8d6609c5452b22a1304c2a10b55c474f1b2a82b07651272758845ac020)

Fresh agents dispatched 2026-10-06 by the caller (Claude Code, Opus 5.5) with only the workspace
root, their own packet path and the verbatim question (closed-book: question only). Returns are
copied verbatim from the task notifications.

## Blind solver A (blind-solver, packet solver-1)

answer: -$0.17 (the low end fell from $5.55 to $5.38)
confidence: high

path:
1. **When the acquisition closed.** D08 (Q1 2026 release, April 16, 2026), line 27: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 lines 203 and 685 give the same date.
2. **Guidance in effect on March 23, 2026.** D07 (Q4 2025 release, Jan. 22, 2026), line 335: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". Lines 17 and 31 say the same. Line 33 says Abbott then still expected the deal "to close in the second quarter of 2026". No document in the packet changes the guidance between Jan. 22 and April 16. D08's headline, "Updates Guidance to Reflect Acquisition of Exact Sciences", shows the update came on April 16. So the low end on March 23 was **$5.55**.
3. **When the ACS reaffirmed Cologuard.** D10 (Q2 2026 release, July 16, 2026), line 39: "In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options…". The release covers the quarter ended June 30, 2026, so this means May 2026.
4. **Guidance in effect in May 2026.** D08 line 223: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences." D10 line 29 confirms this range stayed in place until July 16: "raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58." So the low end in May was **$5.38**.
5. **Calculation.** $5.38 − $5.55 = −$0.17. Check: 5.55 − 5.38 = 0.17.
6. **Source check.** The decisive quotes also appear in the original files under docs/ (abt_ex991_2026-01-22.txt, abt_ex991_2026-04-16.txt and abt_ex991_2026-07-16.txt). These are plain-text sources, so there are no PDF pages or charts to inspect.

minimal_documents: D07, D08, D10
- D07 is the only source for the $5.55 low end in effect on March 23.
- D08 shows the guidance changed on April 16, which is after the closing and before May. D10 alone shows only that $5.38–$5.58 was the range just before July 16, not when it was set.
- D10 is the only source for the ACS reaffirmation in May.
- D08's closing date can be swapped for D10's (lines 203 and 685). No other replacements exist in the packet.

readings:
- **Main reading:** guidance in effect on March 23, 2026 ($5.55) compared with guidance in effect in May 2026 ($5.38) gives **−$0.17**.
- **Using the release that reports the ACS event:** if someone used the July 16 range ($5.45 low end) instead of the guidance in effect in May, the answer would be −$0.10. That is inconsistent with "the month the ACS reaffirmed", which is May. The raise came in July.
- **Treating the first post-closing guidance as the start point:** taking the April 16 guidance ($5.38) as the starting point gives $0.00. This conflicts with "the day it completed", March 23, when the January guidance was still in effect.
- **Removing the $0.20 dilution:** backing out the dilution from the April range gives a $5.58 low end and +$0.03. This is not a printed guidance range, so it is not defensible as "the guidance range".

gaps:
- The packet contains no Abbott statement dated on or close to March 23, 2026. The guidance in effect that day is inferred: the January 22 guidance stands, no packet document changes it, and D08 is labeled as the update.
- D10 says only "In May" for the ACS action, with no exact day. This doesn't matter, because the guidance was unchanged from April 16 to July 16.
- Search coverage: all 11 documents were checked by searches for guidance, EPS, Exact Sciences, ACS, Cologuard and "$5.xx" figures. I read the relevant sections of D07, D08 and D10 directly, plus the opening sections of D09 (litigation notice), D11 (litigation settlement release) and D06 (by-laws). I did not read D01–D04 (2025 results with 2025 guidance) or D05 (merger announcement, no EPS guidance) in full, only through search hits. D06's body was not read beyond its start, but it has no matches for 2026, guidance, Exact or Cologuard.

contaminated: no. The packet directory also contains question.txt. I did not open it, and I used only the question as given.

Files used (all under D:\Dev\Docket\tasks\aq-00745\runs\q07-r0-v2-83dc1c8d6609c5452b22a1304c2a10b55c474f1b2a82b07651272758845ac020\solver-1\):
- text\D07.txt
- text\D08.txt
- text\D10.txt
- docs\abt_ex991_2026-01-22.txt
- docs\abt_ex991_2026-04-16.txt
- docs\abt_ex991_2026-07-16.txt

## Blind solver B (blind-solver, packet solver-2)

**answer:** −$0.17. The low end fell from $5.55 to $5.38.

**confidence:** high

**path:**
1. **When the acquisition closed.** D08 (Q1 2026 release, Apr 16, 2026), line 27: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 says the same at lines 49 and 203: "Abbott acquired on March 23, 2026".
2. **Guidance on that day (March 23, 2026).** The latest full-year 2026 guidance issued before then is in D07 (Jan 22, 2026), lines 31 and 335: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". No packet document changes guidance between Jan 22 and Apr 16. D08's headline (line 15) says it "Updates Guidance to Reflect Acquisition of Exact Sciences", so the update came on Apr 16 and the January range still applied on March 23. D07 line 33 also shows the January range was set before the deal closed: "continues to expect the transaction to close in the second quarter of 2026". **Low end: $5.55.**
3. **Month of the ACS reaffirmation.** D10 (Jul 16, 2026), line 39: "In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options". That is May 2026.
4. **Guidance in May 2026.**
   - It was set on Apr 16 in D08, lines 31 and 223: "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences".
   - It lasted until Jul 16. D10 line 29: "raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58".
   - **Low end in May: $5.38.**
5. **Calculation:** $5.38 − $5.55 = **−$0.17**, a decrease. For context only, the high end fell from $5.80 to $5.58, which is −$0.22.

**minimal_documents:** D07, D08, D10.
- D07 + D10 alone could work, but you would have to assume the "previous range" in D10 was already in place in May. D08 shows it was set on Apr 16.
- The other documents do not replace any of these:
  - D01–D04 are 2025 earnings releases with 2025 guidance only.
  - D05 is the Nov 2025 deal announcement and gives no EPS guidance.
  - D06 is the company by-laws.
  - D09 is a notice of a derivative-lawsuit settlement.
  - D11 is a press release about the preterm infant formula lawsuits.

**readings:**
- If "the day it completed" means the date the completion was reported with new guidance (Apr 16, D08), the change is $5.38 → $5.38 = $0.00. I reject this because the question names the completion day, which the documents give as March 23.
- If you use the July 16 release that reported the ACS news instead of the month of the ACS action, the change is $5.45 − $5.55 = −$0.10. I reject this because the question asks about the month the ACS acted (May), and the July raise came after May.

**gaps:**
- The packet has no closing press release from March 23, 2026. That Abbott did not change guidance that day is inferred from D08's "Updates Guidance to Reflect Acquisition" headline and from the lack of any update between Jan 22 and Apr 16.
- How much I read:
  - In full: D07, D08, D09, D10, D11.
  - Partly: D05 (lines 1–60 plus keyword searches) and D06 (header plus searches).
  - Searches only: D01–D04.
- The manifest lists text-only extraction (no pages, no layout files or PDFs), so there were no original pages to check. I did not open question.txt, as instructed.

**contaminated:** no

Relevant files (under `D:\Dev\Docket\tasks\aq-00745\runs\q07-r0-v2-83dc1c8d6609c5452b22a1304c2a10b55c474f1b2a82b07651272758845ac020\solver-2\text\`): `D07.txt`, `D08.txt`, `D10.txt`, `manifest.json`

## Closed-book solver (question only, no tools used)

answer: -$0.17 (the low end fell from about $5.55 to about $5.38)

confidence: low

basis: From memory. I'm fairly sure Abbott's January 2026 guidance was $5.55–$5.80 and didn't include Exact Sciences, so that range would still have applied on the day the deal closed (I believe early 2026). I have a faint recollection that guidance including Exact's dilution was later cut to about $5.38–$5.58, but I'm not sure of it. I can't reliably recall the month the American Cancer Society reaffirmed Cologuard, or whether guidance changed again by then.

contaminated: no. The only context attached was the user's account email, which has nothing to do with the question. There were no project instructions, memory, documents or hints. I made no tool calls.

## Shortcut auditor (shortcut-auditor, packet shortcut)

answer: **−$0.17.** The low end fell from $5.55 to $5.38.

verdict: clear

shortest_path:
1. **Completion date (March 23, 2026).** D08 line 27 says "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 lines 49 and 203 say the same.
2. **Guidance in force on March 23 (low end $5.55).** D07 (Jan 22, 2026), lines 31 and 335: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". D07 line 33 says Abbott still expected the deal "to close in the second quarter of 2026", so this range left Exact Sciences out. The packet has no guidance change between Jan 22 and Apr 16.
3. **ACS month (May 2026).** D10 line 39: "In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options".
4. **Guidance in force in May (low end $5.38).**
   - D08 (Apr 16, 2026) has the headline "Updates Guidance to Reflect Acquisition of Exact Sciences". Lines 31 and 223 give "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences".
   - D10 (Jul 16, 2026), lines 19 and 29, shows this range stayed in force until July: "raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58".
5. **Calculation:** $5.38 − $5.55 = **−$0.17**. For reference, the high end moved $5.58 − $5.80 = −$0.22.

sufficient_documents: D07 + D08 + D10 (minimal set).
- D07 is the only document with $5.55.
- D10 is the only document with the ACS month.
- D08 shows that the $5.38–$5.58 range was issued April 16, which is after March 23 and before May.
- D07 + D10 alone supply all the numbers and both dates. But D10 calls $5.38–$5.58 only the "previous range", so without D08 a reader can't prove it wasn't already in force on March 23. That makes D08 practically necessary.
- No single document is sufficient, and no document states the move directly. Searches for "0.17", "previous range", "5.55" and "compared to" found the January range only in D07.

searches:
- **Terms:** Exact Sciences; completed/acquired; American Cancer Society / ACS / Cologuard / preferred; "In May" / May 2026; guidance / projects full-year / adjusted diluted EPS; every `$5.xx` value; 0.17; previous / compared to / lowers / raises / updated guidance.
- **Coverage:**
  - I checked all 11 text files through the manifest and targeted searches.
  - I read in full or in part D07, D08, D10, D09 (a notice of settlement in a derivative lawsuit, no guidance), D11 (the August 2026 preterm-infant-formula settlement release, no guidance) and the start of D06 (the By-Laws, with no guidance hits).
  - D01–D04 contain only 2025 guidance.
  - D05 (Nov 2025 deal announcement) mentions ACS only as a footnote citation (line 157), not the May reaffirmation.
- **Fidelity check:** match counts in the original docs/ files for the key phrases agree with the text/ extracts.

readings/gaps:
- **Weaker alternative readings:**
  - Treating "the month ACS reaffirmed" as the July 16 release that reported it gives $5.45 − $5.55 = −$0.10.
  - Treating "the day it completed" as the April 16 release that reported the completion gives $5.38 − $5.38 = $0.00.
  - Using D10 alone and comparing its previous range with its new one gives +$0.07. This is the main **difficulty risk**, since D10 holds both date anchors plus two ranges.
  - D08's "$0.20 of dilution" invites −$0.20, which is wrong because $5.55 − $0.20 = $5.35, not $5.38.
- **Gaps:** The packet has no March 23 closing press release, so a guidance change on the closing day itself can't be ruled out from outside sources. Within the packet, D08's "Updates Guidance" headline and D07's expectation of a Q2 close put the change on April 16. No extraction gaps were found.
- **Contamination:** none. I did not open `question.txt` or any notes, snapshots or other packets.

Relevant files (under `D:\Dev\Docket\tasks\aq-00745\runs\q07-r0-v2-83dc1c8d6609c5452b22a1304c2a10b55c474f1b2a82b07651272758845ac020\shortcut\text\`):
- `D07.txt`
- `D08.txt`
- `D10.txt`
